|
|
|
| home > ict > Autumn 2017 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
|
 |
| |
|
|
|
End Point
Cut Off
Dr Graham Hughes looks to the financial side of clinical trials, wondering how exactly Brexit might affect the pharma and healthcare industry's funding. |
|
|
|
Improving Site Activation
Three-Fold Solution
Sean Stanton at Bioclinica Research Network believes that proper leadership and oversight can protect site start-up from delays and complications caused by miscommunication between the large number of parties involved. |
|
|
Site Selection and Management
Important Choices
CIDP’s Bandana Seesurn acknowledges the difficulties in choosing a trial site, but also looks at the current resources simplifying this process, such as online platforms and other modern communication technology. |
|
|
|
eSource at the Sites
Revolutionary Potential
Mike Novotny and Nick O’Brien at Medrio discuss the difficulties
of getting site staff to adopt new
methods and technologies that
could eliminate paper practices
and provide excellent benefits.
|
|
|
Patient Consent Practices
Shredding Paper
DrugDev Patient Solutions' Eric Delente discusses the integration of eConsent methods into trials in place of out-dated paper consent forms, acknowledging patient empowerment and ease of understanding as key benefits.
|
|
|
Pharmacovigilance Online
Time to Listen
Caroline Legendre and Alexis Pinçon at UBC consider the integration of new technology into pharmacovigilance practices and how platforms offering unique opportunities to hear the collective voice of patients are growing in importance.
|
|
|
Clinical Trial Management Systems
The Connected CTMS
Utilisation of the cloud could reduce expenses and aid process efficiency, solving the problem of increased study complexity caused by the rising number of data sources, suggests Brion Regan at ERT.
|
|
|
|
Event Preview
Coming Together
In this introduction to PCT Europe 2017, we relay the topics that will be covered by experts on 28-29 November in RAI, Amsterdam. |
|
|
|
|
Japanese Clinical Research
Expert Knowledge
According to ICON’s Mary Pan, utilising CROs will overcome the hurdles that currently prevent Japan’s growth in the field of biopharmaceutical R&D.
|
|
|
|
|
Digital Developments
Through the Clouds
Focusing on the use of new technology in data management, Mike Capone at Medidata Solutions shows how machine learning methods have become crucial to production processes thanks to the availability of computing power. |
|
|
|
|
Site Nursing Support
Helping Hands
Improving standards of care is one of the pharma industry’s main goals, and it can lead to a rise in trial recruitment and retention rates. Helena Baker at Medical Research Network highlights how nurse visits are encouraging both.
|
|
|
|
|
Q&A: PCT Europe 2017
Teaming Up
Conference Director Louisa Maitland talks with ICT about the upcoming PCT Europe event, which will offer insight into industry issues.
|
|
|
|
|
Electronic Medical Records
On the Record
Full digital provision of the right patient health information could enable precision medicine to significantly improve disease treatment, and IT is key to enabling this, say Tigran Arzumanov and Le Vin Chin at Clinerion. |
|
|
Spotlight
elluminate® Mapper
This issue’s Spotlight feature is presented by eClinical Solutions, outlining innovations in data management tools that are allowing clinical development teams to become more self-sufficient.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Sustainability, plastics and Brexit: Keynote speakers set to inspire at PPMA Total Show 2019
Experts from IKEA, the British Plastics Federation and The Sunday Times
to create a forum for education, knowledge-sharing and debate
More info >> |
|
 |
White Papers |
 |
|
Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody
RSSL
Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >> |
|
 |
Industry Events |
 |
The Universe of Pre-filled Syringes and Injection Devices
22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel
PDA’s Universe of Pre-filled Syringes and Injection
Devices has become the must-attend meeting for everyone
working in the field, and is now the world’s largest conference on this subject
More info >> |
|
|
